Summary
Depressive illness is a common, often unrecognised and untreated condition with substantial associated costs, particularly indirect costs (e.g. lost productivity and absenteeism).
The improved tolerability profile of fluoxetine and associated lower discontinuation rates, the relative safety of the drug in overdosage and its similar efficacy compared with tricyclic antidepressants have provided the main rationale for using this agent in depressed patients.
Pharmacoeconomic analyses of fluoxetine have mainly sought to determine whether its higher acquisition cost in comparison with tricyclic antidepressants can be offset by reductions in other costs and whether the use of this agent as first-line therapy can be justified. Studies have also attempted to determine whether the selective serotonin reuptake inhibitors (SSRIs) can be distinguished from one another on pharmacoeconomic grounds; overall efficacy and tolerability of these agents appear to be similar, although tolerability data are conflicting.
Most analyses have been of a retrospective database or clinical decision analytic model design; two prospective trials (one conducted in a naturalistic setting) have been conducted. These studies have mainly considered direct treatment costs only from the perspective of the healthcare payer.
Available evidence suggests that overall total direct healthcare costs for patients who start antidepressant therapy with fluoxetine are similar to, or lower than, those for patients who start therapy with tricyclic agents or other SSRIs.
Offsetting of the higher acquisition cost of fluoxetine compared with that of tricyclic agents may be accounted for by lower in- and outpatient costs with fluoxetine, a possible lower risk of absenteeism from work and lower mean total medical costs associated with acute overdosage. Between-treatment differences in drug use patterns may also, in part, explain the observed differences in total healthcare costs between fluoxetine and other antidepressants. In particular, patients beginning therapy with fluoxetine are more likely to receive treatment regimens that meet minimum recommended guidelines for dosage and duration and are less likely to require treatment switching/augmentation than those receiving tricyclic antidepressants or other SSRIs as initial therapy. In addition, fewer fluoxetine than tricyclic antidepressant recipients discontinue therapy early, and fewer fluoxetine recipients require upward dosage titration or concomitant anxiolytic/ hypnotic medications than patients receiving other SSRIs.
In conclusion, fluoxetine is a well established antidepressant which possesses tolerability and safety advantages over the tricyclic agents. The available cost analyses show that these benefits can be obtained without additional overall cost to the healthcare provider. Cost advantages observed to date for fluoxetine over other SSRIs require confirmation.
Similar content being viewed by others
References
Woods SW, Baker CB. Cost-effectiveness of newer antidepressants. Curr Opin Psychiatry 1997 Mar; 10: 95–101
Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry 1996 Apr; 168: 404–9
Henry JA, Rivas CA. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: depression and its treatment. Pharmacoeconomics 1997 May; 11: 419–43
Greenberg PE, Stiglin LE, Finkelstein SN, et al. Depression: a neglected major illness. J Clin Psychiatry 1993 Nov; 54: 419–24
Henry JA. Debits and credits in the management of depression. Br J Psychiatry 1993 Jul; 163 Suppl. 20: 33–9
Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993 Jan; 7: 191–5
Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost—effectiveness of pharmacological treatment. Br J Psychiatry 1994 May; 164: 665–73
Wittchen H-Y, Knäuper B, Kessler RD. Lifetime risk of depression. Br J Psychiatry 1994; 165 Suppl. 26: 16–22
Kessler RC, McGonagle KA, Nelson CB, et al. Sex and depression in the National Comorbidity Survey II: cohort effects. J Affect Disord 1994; 30: 15–26
Lehtinen V, Joukamaa M. Epidemiology of depression: prevalence, risk factors and treatment situation. Acta Psychiatr Scand 1994; 89 Suppl. 377: 7–10
Weissman MM, Bland R, Joyce PR, et al. Sex differences in rates of depression: cross-national perspectives. J Affect Disord 1993 Oct—Nov; 29: 77–84
Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey I: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993; 29: 85–96
MacDonald TM, McMahon AD, Reid IC. Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ 1996 Oct 5; 313: 860–1
Donoghue JM, Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 1996 Feb; 168: 164–8
Katon W, Von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30: 67–76
Santiago JM. The costs of treating depression. J Clin Psychiatry 1993 Nov; 54: 425–6
McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a medicaid population. J Clin Psychiatry 1990; 51 Suppl.: 60–9
Spaner D, Bland RC, Newman SC. Major depressive disorder. Acta Psychiatr Scand 1994; 376 Suppl.: 7–15
Angst J. Epidemiology of depression. Psychopharmacology 1992; 106 Suppl.: S71–4
Hale AS. Juggling cost and benefit in the long-term treatment of depression. Postgrad Med J 1994; 70 Suppl. 2: S2–8
Maynard A. Cost management: the economist’s viewpoint. Br J Psychiatry 1993 Jul; 163 Suppl. 20: 7–13
Katzelnick DJ, Kobak KA, Jefferson JW, et al. Prescribing patterns of antidepressant medications for depression in a HMO. Formulary 1996; 31: 374–88
Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993 Nov; 54: 405–18
Hylan TR, Buesching DP, Tollefson GD. Health economic evaluations of antidepressants: a review. Depression Anxiety. In press
Bingefors K, Isacson D, von Knorring L. Antidepressant dose patterns in Swedish clinical practice. Int Clin Psychopharmacol 1997; 12: 283–90
Saklad SR. Pharmacoeconomic issues in the treatment of depression. Pharmacotherapy 1995 Nov—Dec; 15 (Pt 2): 76S–83S
Lane R, McDonald G. Reducing the economic burden of depression. Int Clin Psychopharmacol 1994 Winter; 9: 229–43
Rupp A, Narrow W, Regier D, et al. Epidemiology and costs of depression: a hidden burden. Dis Manage Health Outcomes 1997 Sep; 2: 134–40
Henry JA, Rivas CA. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost effectiveness analysis. Pharmacoeconomics 1997 Jun; 11: 515–37
Judd LL, Paulus MP, Wells KB, et al. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 1996 Nov; 153: 1411–7
Franco K, Tamburino M, Campbell N, et al. The added costs of depression to medical care. Pharmacoeconomics 1995 Apr; 7: 284–91
Stoudemire A, Frank R, Hedemark N. The economic burden of depression. Gen Hosp Psychiatry 1986 Nov; 8: 387–94
Rupp A. The economic consequences of not treating depression. Br J Psychiatry 1995; 166 Suppl. 27: 29–33
Lewis-Hall FC, Wilson MG, Tepner RG, et al. Fluoxetine vs. tricyclic antidepressants in women with major depressive disorder. J Women Health 1997 Jun; 6: 337–43
Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986 Dec; 32: 481–508
Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995 Jun 3; 310: 1433–8
Edwards JG. Drug choice in depression: selective serotonin reuptake inhibitors or tricyclic antidepressants? CNS Drugs 1995 Aug; 4: 141–59
Steffens DC, Krishnan RR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depression Anxiety 1997; 6: 10–8
Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9 (1): 47–53
Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994 Jan; 10: 18–46
Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996 Jun 26; 275: 1897–902
Le Pen C, Levy E, Ravily V, et al. The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics. J Affect Disord 1994; 31: 1–18
Kernick DP. Which antidepressant? A commentary from general practice on evidence based medicine and health economics. Br J Gen Pract 1997 Feb; 47: 95–8
de Jonghe F, Swinkels J. Selective serotonin reuptake inhibitors: relevance of differences in their pharmacological and clinical profiles. CNS Drugs 1997; 7 (6): 452–67
Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8 (3): 197–202
MacKay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 1997; 6: 235–46
Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J Clin Psychiatry 1995 Jul; 56: 288–96
Wilde MI, Whittington R. Paroxetine: a pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 1995 Jul; 8: 62–81
Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressantuse and their relation to costs of care. Am J Manage Care 1996; 2: 1239–46
Modell JG, Katholi CR, Modell JD, et al. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997 Apr; 61: 476–87
Harris MG, Benfield P. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. Drugs Aging 1995 Jan; 6: 64–84
Pande AC, Sayler ME. Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 1993; 8 (4): 243–5
Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683–7
Stokes PE. Fluoxetine: a five-year review. Clin Ther 1993 Mar—Apr; 15: 216–43
Lane R, Baldwin D, Preskorn S. The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 1995; 9 (2) Suppl.: 163–78
Miller FT, Freilicher J. Comparison of TCAs and SSRIs in the treatment of major depression in hospitalized geriatric patients. J Geriatr Psychiatry Neurol 1995 Jul; 8: 173–6
Smith HA, Wedlund PJ. Depression: its classification, epidemiology, expression and treatment. J Pharmacoepidemiol 1993; 2: 3–34
Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993 Dec; 13 Suppl. 2: 18S–22S
De WJ, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993 Feb; 87: 141–5
Patris M, Bouchard J-M, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996 Jun; 11: 129–36
Rapaport M, Coccaro E, Sheline Y, et al. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996 Oct; 16: 373–8
Noble S, Benfield P. Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 1997; 8 (5): 410–31
Schöne W, Ludwig M. A double—blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993 Dec; 13 Suppl. 2: 34S–9S
Geretsegger C, Böhmer F, Ludwig M. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 1994; 9 (1): 25–9
Trindale E, Menon D. Selective serotonin reuptake inhibitors (SSRIS) for major depression. Part I. Evaluation of the clinical literature. Canadian Co-ordinating Office for Health Technology Assessment. Report 1997: 3E
Finley PR. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother 1994; 28: 1359–69
Donovan S, McGrady H, Pownall R. The efficacy and tolerability of dothiepin and three selective serotonin reuptake inhibitors in the treatment of major depression: a review of six double-blind studies. Curr Ther Res 1993 Sep; 54: 275–89
Robertson MM, Abou-Saleh MT, Harrison DA, et al. A doubleblind controlled comparison of fluoxetine and lofepramine in major depressive illness. J Psychopharmacol 1994; 8 (2): 98–103
Lapierre YD, Joffe R, McKenna K, et al. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. J Psychiatry Neurosci 1997 Mar; 22: 118–26
Fulton B, Benfield P. Moclobemide: an update of its pharmacological properties and therapeutic use. Drugs 1996; 52 (3): 450–74
La Pia S, Giorgio D, Ciriello R, et al. Evaluation of the efficacy, tolerability, and therapeutic profile of fluoxetine versus mianserin in the treatment of depressive disorders in the elderly. Curr Ther Res 1992; 52 (6): 847–58
Haria M, Fitton A, McTavish D. Trazodine: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4 (4): 331–55
Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49 (2): 280–94
Dierick M, Ravizza L, Realini R. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsych Biol Psychiatry 1996 Jan; 20: 57–71
Davis R, Whittington R, Bryson HM. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997 Apr; 53: 608–36
Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/ sleep medications. Clin Ther 1995 Jul—Aug; 17: 786–90
Hylan TR, Neslusan CA, Baldridge M, et al. SSRI antidepressant selection and anxiolytic and sedative-hypnotic use. J Clin Outcomes Manage 1997 Jul—Aug; 4: 16–22
Gregor KJ, Riley JA, Downing DK. Concomitant use of anxiolytics and hypnotics with selective serotonin reuptake inhibitors. Clin Ther 1996 May—Jun; 18: 521–7
Navarro R, Valler WE, Spangler M. Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings. Medical Interface 1995; 8: 114–23
Pathiyal A, Hylan TR, Jones JK, et al. Prescribing of selective serotonin reuptake inhibitors, anxiolytics, and sedative-hypnotics by general practitioners in the Netherlands: a multivariate analysis. Clin Ther 1997; 19 (4): 798–810
Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 1994 Jun; 9 Suppl. 3: 13–9
Sproule BA, Narnajo CA, Bremmer KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions. Clin Pharmacokinet 1997; 33 (6): 454–71
Stahl MMS, Lindquist M, Pettersson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163–9
Stokes PE, Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin Ther 1997; 19 (5): 1135–250
Hoog SL, Fava M, Ascroft RC, et al. Risk of adverse events and depressive symptom breakthrough following brief interruption of selective serotonin reuptake inhibitor therapy in a randomized clinical trial. Indianapolis: Eli Lilly, 1998. (Data on file)
Blomgren SL, Krebs W, Wilson M, et al. SSRI dose interruption study: interim data [abstract no. NR188]. 150th Annual Meeting of the American Psychiatric Association; 1997 May 17- 24; 118, San Diego, California
Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ 1995; 310: 215–8
Feighner JP. Compliance and quality of response are major contributors to cost-effective antidepressant therapy. Hum Psychopharm 1994 Jun; 9 Suppl. 1: S21–23
Buesching DP. The health economics mosaic: reviewing and organizing pharmacoeconomic data for antidepressant selection decisions. Indianapolis: Eli Lilly, 1998. (Data on file)
Mitchell J, Greenberg J, Finch K, et al. Effectiveness and economic impact of antidepressant medications: a review. Am J Manage Care 1997; 3: 323–30
Tracey D. Selective serotonin reuptake inhibitors: commercial interests should not influence prescribing [letter]. BMJ 1994 Oct 22; 309: 1083–4
World Health Organization Mental Health Collaborating Centers. Pharmacotherapy of depressive disorders: WHO consensus statement. J Affect Disord 1989; 17: 197–8
Agency for Health Care Policy Research. Treatment of major depression: clinical practice guidelines, no. 5, vol 2. Rockville (MD): US Department of Health and Human Services, AHCPR Publication no. 93-0550, 1993
American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993; 150 Suppl. 4: 1–26
Montgomery SA, Bebbington P, Cowen P, et al. Guidelines for treating depressive illness with antidepressants: a statement from the British Association for Psychopharmacology. J Psychopharmacol 1993; 7 (1): 19–23
Revicki DA, Luce BR. Pharmacoeconomics research applied to psychopharmacology development and evaluation. Psychopharmacol Bull 1995; 31 (1): 57–65
Hylan TR, Kotsanos JG, Andersen JS, et al. Comparison of a decision analytic model with results from a naturalistic economic clinical trial: an application to evaluating alternative antidepressants. Am J Manage Care 1996; 2: 1211–23
Freemantle N, House A, Mason J, et al. Economics of treatment of depression [letter]. Br J Psychiatry 1995; 166. 397
Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr Serv 1997; 48: 1420–6
Hylan TR, Crown WH, Meneades L, et al. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998; 47: 71–9
Crown WH, Obenchain RL, Englehart L, et al. The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. Stat Med. In press
Woods SW, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. Br J Psychiatry 1997 Mar; 170: 257–63
Freemantle N, House A, Song F, et al. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ 1994 Jul 23; 309: 249–53
Boyer WF, Feighner JP. The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients. In: Jönsson B, Rosenbaum, J, editors. Health economics or depression. Chichester: Wiley, 1993: 65–75
Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994 Jul—Aug; 16: 715–30
Skaer TL, Sclar DA, Robison LM, et al. Antidepressant pharmacotherapy: effect on women’s resource utilization within a health maintenance organization. J Appl Ther 1996; 1: 45–52
Sclar DA, Skaer TL, Robison LM, et al. Economic outcomes with antidepressant pharmacotherapy: a retrospective intentto—treat analysis. (Data on file)
Simon GE, Fishman P. Cost implications of initial antidepressant selection in primary care. Pharmacoeconomics 1998; 13 (1 Pt 1): 61–70
Venturini F, Hay JW. Cost-effectiveness analysis of fluoxetine versus amitriptyline as initial treatment of a major depressive episode in primary care [abstract]. Am J Manage Care 1997 Mar; 3: S25
Souêtre E, Lozet H, Cimarosti I. Predicting factors for absenteeism in patients with major depressive disorders. Eur J Epidemiol 1997 Jan; 13: 87–93
Beuzen JN, Ravily VF, Souetre EJ, et al. Impact of fluoxetine on work loss in depression. Int Clin Psychopharmacol 1993; 8 (4): 319–21
Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Indianapolis: Eli Lilly, 1998. (Data on file)
Obenchain RL, Melfi CA, Croghan TW, et al. Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy. Pharmacoeconomics 1997 May; 11: 464–72
Revicki DA, Palmer CS, Phillips SD, et al. Acute medical costs of fluoxetine versus tricyclic antidepressants: a prospective multicentre study of antidepressant drug overdoses. Pharmacoeconomics 1997 Jan; 11: 48-55
Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995 Nov—Dec; 23: 395–412
Boyer P, Danion JM, Bisserbe JC, et al. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 1998; 13 (1): 157–69
Hylan TR, Crown WH, Meneades L, et al. Tricyclic and SSRI antidepressant drug use patterns in the naturalistic setting: a multivariate analysis. Indianapolis: Eli Lilly, 1998. (Data on file)
Donoghue JM. A comparison of prescribing patterns of selective serotonin reuptake inhibitors in the treatment of depression in primary care in the United Kingdom. J Serotonin Res 1995; 1: 47–51
Donoghue JM. Prescribing patterns of selective serotonin reuptake inhibitors in primary care: a naturalistic follow up study. J Serotonin Res 1996; 4: 267–70
Gregor KJ, Overhage JM, Coons SJ, et al. Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Clin Ther 1994 Mar—Apr; 16 (2): 306–15
Hylan TR, Dossenbach M, Meneades L, et al. Antidepressant use in the psychiatrist setting in Austria: a comparison of citalopram, fluoxetine, and paroxetine. J Serotonin Res. In press
Hylan TR, Meneades L, Crown WH, et al. SSRI antidepressant use patterns and their relation to clinical global impressions scores: a naturalisatic study. Indianapolis: Eli Lilly, 1998. (Data on file)
Sclar DA, Skaer TL, Robison LM, et al. Evidence—based algorithm for antidepressant pharmacotherapy. (Data on file)
Revicki DA, Brown RE, Palmer W, et al. Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics 1995 Dec; 8: 524–40
Revicki DA, Brown RE, Keller MB, et al. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings [abstract]. J Clin Psychiatry 1997 Feb; 58: 47–58
Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a costeffectiveness study of nefazodone. Psychopharmacol Bull 1995; 31 (2): 249–58
Lonnqvist J, Sintonen H, Syvälahti E, et al. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand 1994 Jun; 89: 363–9
Mesters P, Cosyns P, Dejaiffe G, et al. Assessment of quality of life in the treatment of major depressive disorder with fluoxetine,20 mg, in ambulatory patients aged over 60 years. Int Clin Psychopharmacol 1993; 8 (4): 337–40
Heiligenstein JH, Ware JE, Beusterien KM, et al. Acute effects of fluoxetine versus placebo on functional health and wellbeing in late-life depression. Int Psychogeriatr 1995; 7 Suppl.: 125–37
Souêtre E, Martin P, Lozet H, et al. Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. Int Clin Psychopharmacol 1996 Mar; 11: 45–52
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wilde, M.I., Benfield, P. Fluoxetine. Pharmacoeconomics 13, 543–561 (1998). https://doi.org/10.2165/00019053-199813050-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199813050-00007